Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 21 of 21 publications.

Pajouheshnia R, van Smeden M, Peelen LM, Groenwold RHH. Variation in the measurement of predictors affects the discriminative ability and transportability of a prediction model. Presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2, 2018. Utrecht, The Netherlands. [abstract] Diagn Progn Res. 2018 Jul 2; 2(Suppl 1):40. doi: 10.1186/s41512-018-0036-3

Damen JAAG, Debray TPA, Pajouheshnia R, Reitsma JB, Scholten RJPM, Moons KGM, Hooft L. Empirical evidence on the impact of study characteristics on the performance of prognostic models: a meta-epidemiological study. Presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2, 2018. Utrecht, The Netherlands. [abstract] Diagn Progn Res. 2018 Jul 2; 2(Suppl 1):29-30. doi: 10.1186/s41512-018-0036-3

Pajouheshnia R, Schuster NA, Moons KGM, Rutten FH, Groenwold RHH, Peelen LM. Accounting for time-varying treatments when developing a prognostic model: a case study in patients treated with betablockers. Poster presented at the Methods for Evaluation of Medical Prediction Models, Tests and Biomarkers (MEMTAB) 2018 Symposium; July 2018. Utrecht, Netherlands. [abstract] Diagn Progn Res. 2018 Jul; 2(Supp1):28-9. doi: 10.1186/s41512-018-0036-3

Pajouheshnia R, Damen JAAG, Groenwold RHH, Moons KGM, Peelen LM. Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies. Diagn Progn Res. 2017 Sep 26;1:15. doi: 10.1186/s41512-017-0015-0

Heus P, Damen JAAG, Pajhouheshnia R, Scholten RJPM, Reitsma JM, Collins GS, Altman DG, Moons KGM, Hooft L. More than half of the TRIPOD items are inadequately reported in prediction modelling studies. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):27. doi: 10.1186/s41512-016-0001-y

Pajouheshnia R, Groenwold R, Moons K, Reitsma J, Peelen L. The effects of treatment use when externally validating a prediction model that did not include treatment as predictor. Presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; February 2016. Birmingham, United Kingdom. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):12. doi: 10.1186/s41512-016-0001-y

Pajouheshnia R, Damen J, Groenwold R, Moons K, Peelen L. How treatment use is addressed in prognostic research: a systematic review. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):19. doi: 10.1186/s41512-016-0001-y

Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM. Design characteristics of external validation studies influencing the performance of risk prediction models. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 2016. Birmingham, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):21. doi: 10.1186/s41512-016-0001-y

Damen JAAG, Debray TPA, Heus P, Hooft L, Moons KGM, Pajouheshnia R, Reitsma JB, Scholten RJPM. Performance of the Framingham risk models and pooled cohort equations for the prediction of cardiovascular disease in the general population: a meta-analysis. Poster presented at the Methods for Evaluating Medical Tests and Biomarkers 2016 Symposium; July 19, 2016. Birmington, UK. [abstract] Diagn Progn Res. 2017 Feb 16; 1(Suppl 1):20-1. doi: 10.1186/s41512-016-0001-y

White MV, Hogue SL, Bennett ME, Goss D, Millar K, Hollis K, Siegel PH, Wolf RA, Wooddell M, Silvia S. EpiPen4Schools pilot survey: occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting. Allergy Asthma Proc. 2015 Jul;36(4):306-12. doi: 10.2500/aap.2015.36.3859

Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan;31(1):68-75. doi: 10.2500/aap.2010.31.3306

Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, Kaiser HB, Vandewalker ML, Bernstein J, Toler WT, Prillaman BA, Dalal AA, Lee LA, Philpot EE. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009 Mar;30(2):128-38. doi: 10.2500/aap.2009.30.3204

Santanello NC, DeMuro-Mercon CJ, Shah SR, Schenkel EJ, Ratner PH, Norquist JM, Philip G. Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis. Allergy Asthma Proc. 2006 May 1;27(3):231-9.

Sheth KK, Cook CK, Philpot EE, Prillaman BA, Witham LA, Faris MA, Klein KC, Rickard KA. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc. 2004 Mar;25(2):115-20.

Allen DB, Meltzer EO, Lemanske, Jr. RF, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002 Nov;23(6):407-13.

Ratner PH, Howland, 3rd WC, Jacobs RL, Reed KD, Goode-Sellers ST, Prillaman BA, Philpot EE, Cook CK. Relief of sinus pain and pressure with fluticasone propionate aqueous nasal spray: a placebo-controlled trial in patients with allergic rhinitis. Allergy Asthma Proc. 2002 Jul;23(4):259-63.

Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K, Angelsen A, Girman CJ. Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men. Eur Urol. 2001 Jan 1;39(1):36-41.

Campo R, Brullet E, Montserrat A, Calvet X, Rivero E, Brotons C. Topical pharyngeal anesthesia improves tolerance of upper gastrointestinal endoscopy: a randomized double-blind study. Endoscopy. 1995 Nov;27(9):659-64.